Podcast
Questions and Answers
What was the purpose of the first gene therapy trial conducted by Michael Blaese in 1990?
What was the purpose of the first gene therapy trial conducted by Michael Blaese in 1990?
- To provide relief to patients with chronic pain.
- To treat severe combined immunodeficiency (SCID) in a child. (correct)
- To cure hereditary diabetes in children.
- To enhance the immune system in healthy individuals.
Which gene therapy delivery mechanism allows cells to be genetically modified outside the body before reintroducing them?
Which gene therapy delivery mechanism allows cells to be genetically modified outside the body before reintroducing them?
- Somatic cell therapy
- Ex vivo (correct)
- In vivo
- Germ-line therapy
What is the main characteristic of germ-line gene therapy?
What is the main characteristic of germ-line gene therapy?
- It only affects the patient without passing on changes.
- It is the preferred method for treating acute illnesses.
- It allows modifications that are transmissible and permanent. (correct)
- It modifies somatic cells within a specific tissue.
Why is the ex vivo approach preferred for gene therapy targeting circulating blood cells?
Why is the ex vivo approach preferred for gene therapy targeting circulating blood cells?
Which of the following correctly defines somatic cell gene therapy?
Which of the following correctly defines somatic cell gene therapy?
What is the main limitation of germ-line gene therapy as of now?
What is the main limitation of germ-line gene therapy as of now?
Which of the following accurately describes the condition of patients with SCID before treatment?
Which of the following accurately describes the condition of patients with SCID before treatment?
Which of the following mechanisms is NOT typically used in gene therapy?
Which of the following mechanisms is NOT typically used in gene therapy?
What is the main risk associated with using viral vectors in gene therapy?
What is the main risk associated with using viral vectors in gene therapy?
What type of diseases can gene therapy particularly address in young children?
What type of diseases can gene therapy particularly address in young children?
Which genetic defect prevents the formation of T-lymphocytes in SCID patients?
Which genetic defect prevents the formation of T-lymphocytes in SCID patients?
What can result from insertional mutagenesis during gene therapy?
What can result from insertional mutagenesis during gene therapy?
What is the consequence of overexpression of inserted genes in gene therapy?
What is the consequence of overexpression of inserted genes in gene therapy?
What was the primary cause of leukemia in the patients involved in the clinical trial?
What was the primary cause of leukemia in the patients involved in the clinical trial?
What structural advantage do liposomes provide for gene therapy?
What structural advantage do liposomes provide for gene therapy?
Which gene therapy-associated risk involves the potential for disrupting essential genes?
Which gene therapy-associated risk involves the potential for disrupting essential genes?
What was identified as a serious biohazard during the gene therapy clinical trial for SCID?
What was identified as a serious biohazard during the gene therapy clinical trial for SCID?
What prompted the transient moratorium on gene therapy trials in various countries?
What prompted the transient moratorium on gene therapy trials in various countries?
Why are viral vectors utilized in cancer treatments?
Why are viral vectors utilized in cancer treatments?
How can mutations in the RAG1 and RAG2 genes affect SCID patients?
How can mutations in the RAG1 and RAG2 genes affect SCID patients?
What change was made in the new clinical trial for SCID-X after previous complications?
What change was made in the new clinical trial for SCID-X after previous complications?
What is the primary purpose of gene augmentation therapy?
What is the primary purpose of gene augmentation therapy?
What is a potential consequence when viruses infect surrounding healthy tissues during gene therapy?
What is a potential consequence when viruses infect surrounding healthy tissues during gene therapy?
What therapeutic options remain available for parents of ADA deficiency patients?
What therapeutic options remain available for parents of ADA deficiency patients?
Which type of mutation is primarily targeted by gene replacement therapy?
Which type of mutation is primarily targeted by gene replacement therapy?
What advantage do adenovirus vectors have over retrovirus vectors in gene therapy?
What advantage do adenovirus vectors have over retrovirus vectors in gene therapy?
Which method utilizes antisense oligonucleotides to inhibit gene expression?
Which method utilizes antisense oligonucleotides to inhibit gene expression?
Why are lentivirus vectors particularly advantageous in gene therapy?
Why are lentivirus vectors particularly advantageous in gene therapy?
What significant risk is associated with using retroviral vectors in gene therapy?
What significant risk is associated with using retroviral vectors in gene therapy?
What is a common challenge in using CRISPR CAS technology in clinical applications?
What is a common challenge in using CRISPR CAS technology in clinical applications?
What is the role of a foreign antigen gene in targeted killing of specific cells?
What is the role of a foreign antigen gene in targeted killing of specific cells?
Which statement best describes the use of plasmid vectors in gene therapy?
Which statement best describes the use of plasmid vectors in gene therapy?
In which scenario is pre-existing immunity to adenoviruses considered an advantage?
In which scenario is pre-existing immunity to adenoviruses considered an advantage?
What is the primary purpose of gene therapy for ADA deficiency?
What is the primary purpose of gene therapy for ADA deficiency?
What was a significant limitation observed in the first trial of ADA gene therapy?
What was a significant limitation observed in the first trial of ADA gene therapy?
What approach was taken in the second trial of ADA gene therapy conducted in 2002?
What approach was taken in the second trial of ADA gene therapy conducted in 2002?
What condition is associated with SCID-X as discussed in the document?
What condition is associated with SCID-X as discussed in the document?
What was a prerequisite for patients to be eligible for the SCID-X clinical trial?
What was a prerequisite for patients to be eligible for the SCID-X clinical trial?
What significant finding was documented about patients in the SCID-X trial?
What significant finding was documented about patients in the SCID-X trial?
What potential negative effect was reported in the SCID-X gene therapy study?
What potential negative effect was reported in the SCID-X gene therapy study?
What is a key factor for the effectiveness of gene therapy in SCID-X patients?
What is a key factor for the effectiveness of gene therapy in SCID-X patients?
Which of the following treatment options was NOT initially favored for ADA deficiency patients?
Which of the following treatment options was NOT initially favored for ADA deficiency patients?
In the context of gene therapy for SCID-X, what does the term 'retro mutation' refer to?
In the context of gene therapy for SCID-X, what does the term 'retro mutation' refer to?
What is the primary distinction between gene augmentation and gene replacement strategies in gene therapy?
What is the primary distinction between gene augmentation and gene replacement strategies in gene therapy?
How does the mechanism of targeted inhibition of gene expression differ from gene augmentation therapy?
How does the mechanism of targeted inhibition of gene expression differ from gene augmentation therapy?
What role do viral vectors play in gene therapy, and what is a significant risk associated with their use?
What role do viral vectors play in gene therapy, and what is a significant risk associated with their use?
What advantages do adeno-associated viruses offer over retroviruses in gene therapy applications?
What advantages do adeno-associated viruses offer over retroviruses in gene therapy applications?
How does the use of lentiviral vectors aid in targeting treatments for non-dividing cells?
How does the use of lentiviral vectors aid in targeting treatments for non-dividing cells?
Describe the main difference between in vivo and ex vivo gene therapy delivery methods.
Describe the main difference between in vivo and ex vivo gene therapy delivery methods.
What is the key characteristic of somatic cell gene therapy compared to germ-line gene therapy?
What is the key characteristic of somatic cell gene therapy compared to germ-line gene therapy?
Explain the significance of targeted killing of specific cells in gene therapy.
Explain the significance of targeted killing of specific cells in gene therapy.
What challenges does gene therapy face regarding the use of viral vectors?
What challenges does gene therapy face regarding the use of viral vectors?
What are the potential long-term effects of gene therapy for patients treated for severe combined immunodeficiency (SCID)?
What are the potential long-term effects of gene therapy for patients treated for severe combined immunodeficiency (SCID)?
What is the primary limitation of using herpes simplex viruses as vectors in gene therapy?
What is the primary limitation of using herpes simplex viruses as vectors in gene therapy?
Explain the reason why adverse responses to viral vectors can hinder gene therapy success.
Explain the reason why adverse responses to viral vectors can hinder gene therapy success.
What impact does a mutation in the common γchain gene have on T-cell maturation?
What impact does a mutation in the common γchain gene have on T-cell maturation?
Describe the role of RAG1 and RAG2 genes in T-cell development.
Describe the role of RAG1 and RAG2 genes in T-cell development.
What is insertional mutagenesis and how can it affect gene therapy outcomes?
What is insertional mutagenesis and how can it affect gene therapy outcomes?
How do liposomes facilitate gene transfer into target cells?
How do liposomes facilitate gene transfer into target cells?
What critical challenge is associated with the overexpression of inserted genes in gene therapy?
What critical challenge is associated with the overexpression of inserted genes in gene therapy?
Identify a possible risk factor when using adenoviral vectors in gene therapy.
Identify a possible risk factor when using adenoviral vectors in gene therapy.
What are the implications of using naked DNA in gene therapy?
What are the implications of using naked DNA in gene therapy?
Why is gene therapy a critical option for treating severe combined immunodeficiency (SCID)?
Why is gene therapy a critical option for treating severe combined immunodeficiency (SCID)?
Flashcards are hidden until you start studying
Study Notes
Overview of Gene Therapy
- Gene therapy began in clinical trials during the 1990s, representing an innovative method for treating monogenic disorders.
- The first gene therapy approach was applied by Michael Blaese in 1990 on a child with Severe Combined Immunodeficiency (SCID).
Gene Therapy Definition
- Involves modifying cells to treat or alleviate diseases through genetic modification.
- Two primary delivery methods: in vivo (direct cell treatment) and ex vivo (cells modified outside the body before transplantation).
Types of Gene Therapy
- Germ-line Gene Therapy: Modifies gametes or embryos; changes are heritable. No examples in humans yet.
- Somatic Gene Therapy: Modifies non-germline cells; changes are not inherited, targeting specific diseases.
Mechanisms of Genetic Modification
- Gene Augmentation: Addition of a normal gene to counteract a defective gene, effective in loss-of-function mutations.
- Gene Replacement: Replacing the defective gene with a normal gene, often utilizing homologous recombination.
- Targeted Cell Killing: Equips immune cells to attack diseased cells using genes for antigens/cytokines.
- Inhibition of Gene Expression: Utilizes tools like antisense oligonucleotides to block harmful proteins from mutated genes.
Gene Transfer Process
- Requires cloning the therapeutic gene and selecting a method to deliver it into the patient’s cells.
- The therapeutic gene can integrate into the cell genome or exist as an episome, affecting its persistence through cell division.
Vectors in Gene Therapy
- Viral Vectors: Commonly used; include retroviruses, adenoviruses, adeno-associated viruses, and herpes simplex viruses.
- Non-Viral Vectors: Include liposomes and plasmids; used for targeted delivery of genetic materials.
Risks Associated with Gene Therapy
- Adverse Immune Reactions: Immune response against the vector can compromise treatment success. Notable case in 1999 with a patient who died from an immune response to an adenoviral vector.
- Insertional Mutagenesis: Risk of activating cancer-promoting genes or deactivating essential genes through vector integration.
- Viral Infection of Healthy Tissue: Risk of unintended gene transfer to non-target cells.
- Protein Overproduction: Excessive expression of inserted genes can lead to harmful effects.
Gene Therapy for SCID
- SCID leads to fatal outcomes in children; traditional treatment includes bone marrow transplantation, which is limited by donor availability.
- Gene therapy emerged as an alternative, especially for ADA deficiency, involving ex vivo modifications of T-cell precursors.
Notable Clinical Trials
- Initial trials for ADA-deficient SCID utilized retroviral vectors to introduce a normal ADA gene, showing promise in transducing T-cells and improving patient conditions.
- SCID-X trial utilized retroviral vectors to treat a different form of SCID linked to mutations in the common γchain, allowing for the development of mature T-cells from transduced precursors.
Conclusion of Trials
- The importance of selective advantage for transduced cells was underscored, as initial trials involving oral enzymatic replacement alongside gene therapy impeded effective evaluation of gene therapy efficacy.
- Subsequent trials focusing solely on gene therapy for SCID-X demonstrated successful outcomes with the re-establishment of mature T-cells in patients.### Gene Therapy and Long-term Effects
- Correction of disease observed for over five years in patients receiving gene therapy.
- Most mature T and NK cells in patients expressed the transgene, allowing for reconstitution of peripheral T-cell repertoire.
- Documented negative effects include the development of leukemia in some patients after therapy.
Cases of Leukemia after Gene Therapy
- French study involved ten patients; three developed leukemia within three years post-treatment.
- Leukemia caused by integration of retroviral DNA next to an oncogene.
- Insertional mutagenesis occurred when retroviral vector integrated near proto-oncogenes causing activation.
- All three leukemia cases exploited the same genomic site adjacent to LMO-2 proto-oncogene.
- One patient died, while two were treated successfully for leukemia.
Regulatory Response to Gene Therapy
- Early clinical trials for Severe Combined Immunodeficiency (SCID) faced biohazard issues, leading to a worldwide moratorium on gene therapy.
- Regulatory responses initiated in the USA and Europe, resulting in temporary suspensions of trials.
- Moratorium began in the USA and spread to UK, France, Italy, and Germany.
- Therapy allowed to continue subsequently on a case-by-case basis due to lack of alternative treatments for patients with severe conditions.
Advances and Approval of Gene Therapy
- Studies focused on understanding insertional mutagenesis linked to specific viral vectors.
- New clinical trials for SCID-X resumed with modifications in retroviral vector types to improve safety.
- Clinical trials for ADA deficiency showed no adverse side effects, leading to positive conclusions on the safety and efficacy of gene therapy for these patients.
- In 2016, gene therapy for ADA deficiency received approval in Europe as a standard treatment option.
- Parents can choose between bone marrow transplantation or gene therapy for their children.
- Approval process for gene therapy in the US is ongoing.
Overview of Gene Therapy
- Gene therapy began in clinical trials during the 1990s, representing an innovative method for treating monogenic disorders.
- The first gene therapy approach was applied by Michael Blaese in 1990 on a child with Severe Combined Immunodeficiency (SCID).
Gene Therapy Definition
- Involves modifying cells to treat or alleviate diseases through genetic modification.
- Two primary delivery methods: in vivo (direct cell treatment) and ex vivo (cells modified outside the body before transplantation).
Types of Gene Therapy
- Germ-line Gene Therapy: Modifies gametes or embryos; changes are heritable. No examples in humans yet.
- Somatic Gene Therapy: Modifies non-germline cells; changes are not inherited, targeting specific diseases.
Mechanisms of Genetic Modification
- Gene Augmentation: Addition of a normal gene to counteract a defective gene, effective in loss-of-function mutations.
- Gene Replacement: Replacing the defective gene with a normal gene, often utilizing homologous recombination.
- Targeted Cell Killing: Equips immune cells to attack diseased cells using genes for antigens/cytokines.
- Inhibition of Gene Expression: Utilizes tools like antisense oligonucleotides to block harmful proteins from mutated genes.
Gene Transfer Process
- Requires cloning the therapeutic gene and selecting a method to deliver it into the patient’s cells.
- The therapeutic gene can integrate into the cell genome or exist as an episome, affecting its persistence through cell division.
Vectors in Gene Therapy
- Viral Vectors: Commonly used; include retroviruses, adenoviruses, adeno-associated viruses, and herpes simplex viruses.
- Non-Viral Vectors: Include liposomes and plasmids; used for targeted delivery of genetic materials.
Risks Associated with Gene Therapy
- Adverse Immune Reactions: Immune response against the vector can compromise treatment success. Notable case in 1999 with a patient who died from an immune response to an adenoviral vector.
- Insertional Mutagenesis: Risk of activating cancer-promoting genes or deactivating essential genes through vector integration.
- Viral Infection of Healthy Tissue: Risk of unintended gene transfer to non-target cells.
- Protein Overproduction: Excessive expression of inserted genes can lead to harmful effects.
Gene Therapy for SCID
- SCID leads to fatal outcomes in children; traditional treatment includes bone marrow transplantation, which is limited by donor availability.
- Gene therapy emerged as an alternative, especially for ADA deficiency, involving ex vivo modifications of T-cell precursors.
Notable Clinical Trials
- Initial trials for ADA-deficient SCID utilized retroviral vectors to introduce a normal ADA gene, showing promise in transducing T-cells and improving patient conditions.
- SCID-X trial utilized retroviral vectors to treat a different form of SCID linked to mutations in the common γchain, allowing for the development of mature T-cells from transduced precursors.
Conclusion of Trials
- The importance of selective advantage for transduced cells was underscored, as initial trials involving oral enzymatic replacement alongside gene therapy impeded effective evaluation of gene therapy efficacy.
- Subsequent trials focusing solely on gene therapy for SCID-X demonstrated successful outcomes with the re-establishment of mature T-cells in patients.### Gene Therapy and Long-term Effects
- Correction of disease observed for over five years in patients receiving gene therapy.
- Most mature T and NK cells in patients expressed the transgene, allowing for reconstitution of peripheral T-cell repertoire.
- Documented negative effects include the development of leukemia in some patients after therapy.
Cases of Leukemia after Gene Therapy
- French study involved ten patients; three developed leukemia within three years post-treatment.
- Leukemia caused by integration of retroviral DNA next to an oncogene.
- Insertional mutagenesis occurred when retroviral vector integrated near proto-oncogenes causing activation.
- All three leukemia cases exploited the same genomic site adjacent to LMO-2 proto-oncogene.
- One patient died, while two were treated successfully for leukemia.
Regulatory Response to Gene Therapy
- Early clinical trials for Severe Combined Immunodeficiency (SCID) faced biohazard issues, leading to a worldwide moratorium on gene therapy.
- Regulatory responses initiated in the USA and Europe, resulting in temporary suspensions of trials.
- Moratorium began in the USA and spread to UK, France, Italy, and Germany.
- Therapy allowed to continue subsequently on a case-by-case basis due to lack of alternative treatments for patients with severe conditions.
Advances and Approval of Gene Therapy
- Studies focused on understanding insertional mutagenesis linked to specific viral vectors.
- New clinical trials for SCID-X resumed with modifications in retroviral vector types to improve safety.
- Clinical trials for ADA deficiency showed no adverse side effects, leading to positive conclusions on the safety and efficacy of gene therapy for these patients.
- In 2016, gene therapy for ADA deficiency received approval in Europe as a standard treatment option.
- Parents can choose between bone marrow transplantation or gene therapy for their children.
- Approval process for gene therapy in the US is ongoing.
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.
